This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ciglitazone
Accession Number
DB09201
Type
Small Molecule
Groups
Experimental
Description

Ciglitazone (INN) is a thiazolidinedione. Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.

Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to the market.

Ciglitazone significantly decreases VEGF production by human granulosa cells in an in vitro study, and may potentially be used in ovarian hyperstimulation syndrome. Ciglitazone is a potent and selective PPARγ ligand. It binds to the PPARγ ligand-binding domain with an EC50 of 3.0 µM. Ciglitazone is active in vivo as an anti-hyperglycemic agent in the ob/ob murine model. Inhibits HUVEC differentiation and angiogenesis and also stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
U8QXS1WU8G
CAS number
74772-77-3
Weight
Average: 333.45
Monoisotopic: 333.139864779
Chemical Formula
C18H23NO3S
InChI Key
YZFWTZACSRHJQD-UHFFFAOYSA-N
InChI
InChI=1S/C18H23NO3S/c1-18(9-3-2-4-10-18)12-22-14-7-5-13(6-8-14)11-15-16(20)19-17(21)23-15/h5-8,15H,2-4,9-12H2,1H3,(H,19,20,21)
IUPAC Name
5-({4-[(1-methylcyclohexyl)methoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione
SMILES
CC1(COC2=CC=C(CC3SC(=O)NC3=O)C=C2)CCCCC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UPeroxisome proliferator-activated receptor gammaNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetohexamideCiglitazone may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Ciglitazone.Approved, Vet Approved
AlclometasoneThe metabolism of Ciglitazone can be decreased when combined with Alclometasone.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Ciglitazone.Approved
AmiodaroneThe metabolism of Ciglitazone can be decreased when combined with Amiodarone.Approved, Investigational
AripiprazoleThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Aripiprazole.Approved, Investigational
Arsenic trioxideThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Asenapine.Approved
AtazanavirThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Atazanavir.Approved, Investigational
AzithromycinThe metabolism of Ciglitazone can be decreased when combined with Azithromycin.Approved
BendroflumethiazideThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Bendroflumethiazide.Approved
BenzthiazideThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Benzthiazide.Approved
BetamethasoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BortezomibThe metabolism of Ciglitazone can be decreased when combined with Bortezomib.Approved, Investigational
BrexpiprazoleThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Brexpiprazole.Approved, Investigational
BumetanideThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Bumetanide.Approved
BuserelinThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Buserelin.Approved, Investigational
CabergolineThe metabolism of Ciglitazone can be decreased when combined with Cabergoline.Approved
CalcitriolThe metabolism of Ciglitazone can be increased when combined with Calcitriol.Approved, Nutraceutical
CarbamazepineThe metabolism of Ciglitazone can be increased when combined with Carbamazepine.Approved, Investigational
CarbutamideCiglitazone may increase the hypoglycemic activities of Carbutamide.Experimental
CeritinibThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Ceritinib.Approved
CevimelineThe metabolism of Ciglitazone can be decreased when combined with Cevimeline.Approved
ChlorothiazideThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideCiglitazone may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Chlorthalidone.Approved
CholecalciferolThe metabolism of Ciglitazone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiprofloxacinThe therapeutic efficacy of Ciglitazone can be increased when used in combination with Ciprofloxacin.Approved, Investigational
CitalopramThe risk or severity of hypoglycemia can be increased when Citalopram is combined with Ciglitazone.Approved
Clobetasol propionateThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Clobetasol propionate.Approved
ClotrimazoleThe metabolism of Ciglitazone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Clozapine.Approved
CorticotropinThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Corticotropin.Approved, Investigational, Vet Approved
Cortisone acetateThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Cortisone acetate.Approved, Investigational
CyclobenzaprineCyclobenzaprine may decrease the hypoglycemic activities of Ciglitazone.Approved
CyclopenthiazideThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Cyclopenthiazide.Approved
CyclosporineThe metabolism of Ciglitazone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
DabrafenibThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Dabrafenib.Approved, Investigational
DanazolThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Danazol.Approved
DapsoneThe metabolism of Ciglitazone can be decreased when combined with Dapsone.Approved, Investigational
DarunavirThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Darunavir.Approved
DesogestrelThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Desogestrel.Approved
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Ciglitazone.Approved, Investigational
DexamethasoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
DiazoxideThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Diazoxide.Approved
DienogestThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Dienogest.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Ciglitazone.Approved, Investigational
DiltiazemThe metabolism of Ciglitazone can be decreased when combined with Diltiazem.Approved, Investigational
DisopyramideThe risk or severity of hypoglycemia can be increased when Disopyramide is combined with Ciglitazone.Approved
DofetilideThe metabolism of Dofetilide can be decreased when combined with Ciglitazone.Approved, Investigational
DoxepinDoxepin may decrease the hypoglycemic activities of Ciglitazone.Approved, Investigational
DoxycyclineThe metabolism of Ciglitazone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DrospirenoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Drospirenone.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Ciglitazone.Approved, Investigational
EpinephrineThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Epinephrine.Approved, Vet Approved
EpitizideThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Epitizide.Experimental
ErgocalciferolThe metabolism of Ciglitazone can be decreased when combined with Ergocalciferol.Approved, Nutraceutical
ErythromycinThe metabolism of Ciglitazone can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EstradiolThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Estradiol.Approved, Investigational, Vet Approved
Estrone sulfateThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Etacrynic acid.Approved, Investigational
EthinylestradiolThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Ethinyl Estradiol.Approved
Ethynodiol diacetateThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Ethynodiol diacetate.Approved
EtonogestrelThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoposideThe metabolism of Ciglitazone can be increased when combined with Etoposide.Approved
EverolimusThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Everolimus.Approved
FelodipineThe metabolism of Ciglitazone can be decreased when combined with Felodipine.Approved, Investigational
FluconazoleThe metabolism of Ciglitazone can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Fludrocortisone.Approved, Investigational
FlunisolideThe metabolism of Ciglitazone can be increased when combined with Flunisolide.Approved, Investigational
Fluocinolone acetonideThe metabolism of Ciglitazone can be increased when combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluorometholoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Fluorometholone.Approved, Investigational
FluoxetineThe risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Ciglitazone.Approved, Vet Approved
FluvastatinThe metabolism of Ciglitazone can be increased when combined with Fluvastatin.Approved
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Ciglitazone.Approved, Investigational
FosamprenavirThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Fosamprenavir.Approved
FurosemideThe therapeutic efficacy of Ciglitazone can be increased when used in combination with Furosemide.Approved, Vet Approved
GemfibrozilThe metabolism of Ciglitazone can be decreased when combined with Gemfibrozil.Approved
GlibornurideCiglitazone may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideCiglitazone may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be increased when used in combination with Ciglitazone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be increased when used in combination with Ciglitazone.Approved, Investigational
GliquidoneCiglitazone may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideCiglitazone may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburideThe therapeutic efficacy of Glyburide can be increased when used in combination with Ciglitazone.Approved
GoserelinThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Goserelin.Approved
HaloperidolThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Haloperidol.Approved
HistrelinThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Histrelin.Approved
HydrochlorothiazideThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
IloperidoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Iloperidone.Approved
ImipramineImipramine may decrease the hypoglycemic activities of Ciglitazone.Approved
IndapamideThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Indapamide.Approved
IndomethacinThe risk or severity of hypoglycemia can be increased when Indomethacin is combined with Ciglitazone.Approved, Investigational
Insulin AspartCiglitazone may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirCiglitazone may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineCiglitazone may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineCiglitazone may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanCiglitazone may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproCiglitazone may increase the hypoglycemic activities of Insulin Lispro.Approved
IsradipineThe metabolism of Ciglitazone can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Ciglitazone can be decreased when combined with Itraconazole.Approved, Investigational
LanreotideThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Lanreotide.Approved
LeuprolideThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Leuprolide.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LiothyronineThe metabolism of Ciglitazone can be decreased when combined with Liothyronine.Approved, Vet Approved
Lipoic AcidThe risk or severity of hypoglycemia can be increased when Lipoic Acid is combined with Ciglitazone.Approved, Investigational, Nutraceutical
LopinavirThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Lopinavir.Approved
LosartanThe metabolism of Ciglitazone can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Lovastatin can be decreased when combined with Ciglitazone.Approved, Investigational
LurasidoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Lurasidone.Approved, Investigational
MecaserminCiglitazone may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MedrogestoneThe serum concentration of Ciglitazone can be decreased when it is combined with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
MedrysoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Medrysone.Approved
Megestrol acetateThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MesalazineMesalazine may increase the hypoglycemic activities of Ciglitazone.Approved
MestranolThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Mestranol.Approved
MetahexamideCiglitazone may increase the hypoglycemic activities of Metahexamide.Experimental
MethotrimeprazineThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
MethyclothiazideThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Methyclothiazide.Approved
Methyl salicylateMethyl salicylate may increase the hypoglycemic activities of Ciglitazone.Approved, Vet Approved
MethylprednisoloneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MetolazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Metolazone.Approved
MibefradilThe metabolism of Ciglitazone can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Ciglitazone can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MifepristoneCiglitazone may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
Mometasone furoateThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Mometasone furoate.Approved, Vet Approved
MoxifloxacinThe therapeutic efficacy of Ciglitazone can be increased when used in combination with Moxifloxacin.Approved, Investigational
NateglinideCiglitazone may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NelfinavirThe metabolism of Ciglitazone can be decreased when combined with Nelfinavir.Approved
NevirapineThe metabolism of Ciglitazone can be increased when combined with Nevirapine.Approved
NiacinThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NicardipineThe metabolism of Ciglitazone can be decreased when combined with Nicardipine.Approved, Investigational
NilotinibThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Nilotinib.Approved, Investigational
NorethisteroneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Norethisterone.Approved
NorgestimateThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Norgestimate.Approved, Investigational
NortriptylineNortriptyline may decrease the hypoglycemic activities of Ciglitazone.Approved
OctreotideThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Octreotide.Approved, Investigational
OlanzapineThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Olanzapine.Approved, Investigational
OxiconazoleThe metabolism of Ciglitazone can be increased when combined with Oxiconazole.Approved
PaliperidoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Paliperidone.Approved
PantoprazoleThe metabolism of Ciglitazone can be increased when combined with Pantoprazole.Approved
ParoxetineThe risk or severity of hypoglycemia can be increased when Paroxetine is combined with Ciglitazone.Approved, Investigational
PasireotideThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Pasireotide.Approved
PegvisomantThe risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ciglitazone.Approved
PentamidineThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Pentamidine.Approved, Investigational
PhenobarbitalThe metabolism of Ciglitazone can be increased when combined with Phenobarbital.Approved, Investigational
PhenytoinThe metabolism of Phenytoin can be decreased when combined with Ciglitazone.Approved, Vet Approved
PiperazineThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Pipotiazine.Approved, Investigational
PolythiazideThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Polythiazide.Approved
PrednisoloneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of weight gain and edema formation can be increased when Pregabalin is combined with Ciglitazone.Approved, Illicit, Investigational
ProgesteroneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Progesterone.Approved, Vet Approved
PseudoephedrineThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Pseudoephedrine.Approved
PyrimethamineThe metabolism of Ciglitazone can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuetiapineThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Quetiapine.Approved
QuinethazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Quinethazone.Approved
QuinineCiglitazone may increase the hypoglycemic activities of Quinine.Approved
RanolazineThe metabolism of Ciglitazone can be decreased when combined with Ranolazine.Approved, Investigational
RepaglinideCiglitazone may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RifampicinThe metabolism of Ciglitazone can be increased when combined with Rifampicin.Approved
RisperidoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Risperidone.Approved, Investigational
RitonavirThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Ritonavir.Approved, Investigational
RosiglitazoneThe metabolism of Ciglitazone can be decreased when combined with Rosiglitazone.Approved, Investigational
RosuvastatinThe therapeutic efficacy of Ciglitazone can be increased when used in combination with Rosuvastatin.Approved
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Ciglitazone.Approved, Investigational, Vet Approved
SaquinavirThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Saquinavir.Approved, Investigational
SertralineThe risk or severity of hypoglycemia can be increased when Sertraline is combined with Ciglitazone.Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Ciglitazone.Approved, Investigational
Silver sulfadiazineThe therapeutic efficacy of Ciglitazone can be increased when used in combination with Silver sulfadiazine.Approved, Vet Approved
SirolimusThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Sirolimus.Approved, Investigational
SulfacetamideThe therapeutic efficacy of Ciglitazone can be increased when used in combination with Sulfacetamide.Approved
SulfadiazineCiglitazone may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleCiglitazone may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfanilamideThe therapeutic efficacy of Ciglitazone can be increased when used in combination with Sulfanilamide.Approved
SulfasalazineSulfasalazine may increase the hypoglycemic activities of Ciglitazone.Approved
SulfisoxazoleThe therapeutic efficacy of Ciglitazone can be increased when used in combination with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe therapeutic efficacy of Ciglitazone can be increased when used in combination with Sumatriptan.Approved, Investigational
SunitinibCiglitazone may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TacrolimusThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Tacrolimus.Approved, Investigational
TamoxifenThe metabolism of Ciglitazone can be decreased when combined with Tamoxifen.Approved
TemazepamThe metabolism of Ciglitazone can be decreased when combined with Temazepam.Approved, Investigational
TemsirolimusThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Temsirolimus.Approved
TerbinafineThe metabolism of Ciglitazone can be increased when combined with Terbinafine.Approved, Investigational, Vet Approved
Testosterone cypionateTestosterone cypionate may increase the hypoglycemic activities of Ciglitazone.Approved
Testosterone enanthateTestosterone enanthate may increase the hypoglycemic activities of Ciglitazone.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Ciglitazone.Approved
TiclopidineThe metabolism of Ciglitazone can be decreased when combined with Ticlopidine.Approved
TipranavirThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Tipranavir.Approved, Investigational
TolazamideCiglitazone may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideCiglitazone may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TorasemideThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Torasemide.Approved
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Ciglitazone.Approved, Investigational
TrazodoneThe risk or severity of hypoglycemia can be increased when Trazodone is combined with Ciglitazone.Approved, Investigational
TriamcinoloneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TrichlormethiazideThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TrimethoprimThe metabolism of Ciglitazone can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may decrease the hypoglycemic activities of Ciglitazone.Approved
TriptorelinThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Triptorelin.Approved, Vet Approved
Trolamine salicylateTrolamine salicylate may increase the hypoglycemic activities of Ciglitazone.Approved
UbidecarenoneThe therapeutic efficacy of Ciglitazone can be increased when used in combination with Ubidecarenone.Approved, Investigational, Nutraceutical
VenlafaxineVenlafaxine may increase the hypoglycemic activities of Ciglitazone.Approved
VerapamilThe metabolism of Ciglitazone can be decreased when combined with Verapamil.Approved
VorinostatThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Vorinostat.Approved, Investigational
ZiprasidoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Ziprasidone.Approved
Food Interactions
Not Available

References

General References
  1. Pershadsingh HA, Szollosi J, Benson S, Hyun WC, Feuerstein BG, Kurtz TW: Effects of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension. 1993 Jun;21(6 Pt 2):1020-3. [PubMed:8505086]
  2. Imoto H, Imamiya E, Momose Y, Sugiyama Y, Kimura H, Sohda T: Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives. Chem Pharm Bull (Tokyo). 2002 Oct;50(10):1349-57. [PubMed:12372861]
  3. Sohda T, Kawamatsu Y, Fujita T, Meguro K, Ikeda H: [Discovery and development of a new insulin sensitizing agent, pioglitazone]. Yakugaku Zasshi. 2002 Nov;122(11):909-18. [PubMed:12440149]
  4. Shah DK, Menon KM, Cabrera LM, Vahratian A, Kavoussi SK, Lebovic DI: Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro. Fertil Steril. 2010 Apr;93(6):2042-7. doi: 10.1016/j.fertnstert.2009.02.059. Epub 2009 Apr 1. [PubMed:19342033]
  5. Xin X, Yang S, Kowalski J, Gerritsen ME: Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem. 1999 Mar 26;274(13):9116-21. [PubMed:10085162]
External Links
KEGG Drug
D03493
PubChem Compound
2750
PubChem Substance
310265109
ChemSpider
2648
ChEBI
64227
ChEMBL
CHEMBL7002
Wikipedia
Ciglitazone

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00534 mg/mLALOGPS
logP3.93ALOGPS
logP4.28ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)6.61ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area55.4 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity91.26 m3·mol-1ChemAxon
Polarizability36.36 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Not Available
Direct Parent
Phenol ethers
Alternative Parents
Phenoxy compounds / Thiazolidinediones / Alkyl aryl ethers / Dicarboximides / Thiocarbamic acid derivatives / Organic carbonic acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides
show 2 more
Substituents
Phenoxy compound / Phenol ether / Alkyl aryl ether / Thiazolidinedione / Monocyclic benzene moiety / Dicarboximide / Thiazolidine / Thiocarbamic acid derivative / Carbonic acid derivative / Organoheterocyclic compound
show 12 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
aromatic ether, thiazolidinone (CHEBI:64227)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
Gene Name
PPARG
Uniprot ID
P37231
Uniprot Name
Peroxisome proliferator-activated receptor gamma
Molecular Weight
57619.58 Da
References
  1. Wick M, Hurteau G, Dessev C, Chan D, Geraci MW, Winn RA, Heasley LE, Nemenoff RA: Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol. 2002 Nov;62(5):1207-14. [PubMed:12391285]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ: Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14. doi: 10.1016/j.clpt.2004.12.266. [PubMed:15900286]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ: Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14. doi: 10.1016/j.clpt.2004.12.266. [PubMed:15900286]

Drug created on October 16, 2015 16:20 / Updated on August 08, 2018 12:15